Everything below concerns Phase 3 trial. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-13. Numbers and descriptions here follow the published literature rather than marketing material.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized cake in single-use vials |
| Solubility class | Freely soluble in water | Reconstituted with sterile diluent before injection |
| Typical storage temperature | 2 to 8 degrees Celsius | Before reconstitution; protect from light |
| Typical analytical method | Reversed-phase high-performance liquid chromatography | Purity and related-substance testing |
| Identity confirmation | Mass spectrometry | Observed mass near 5.1 kDa for the intact peptide |
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
Lyophilized tesamorelin is generally stored refrigerated at temperatures between 2 and 8 degrees Celsius. The solid form is comparatively stable when kept dry and protected from light. Moisture uptake can promote aggregation and degradation, so sealed containers with desiccant are common. Researchers typically avoid repeated temperature cycling, which may stress the peptide. Documentation accompanying reference materials usually specifies a shelf life under these conditions.
Leucine-rich repeat protein SHOC-2 is a protein that in humans is encoded by the SHOC2 gene. This protein was initially identified in Caenorhabditis elegans as SUR-8/SOC2 and was found to be a critical positive regulator of the ERK1/2 signaling pathway that integrates the Ras and RAF components of the ERK1/2 pathway into a multiprotein complex. Specifically, SHOC2 tethers RAS and PP1C proteins and in close proximity to RAF to dephosphorylate “S259” to enable MAPK signaling. The best-studied role of SHOC2 is in modulating signals of the extracellular signal-regulated kinase 1 and 2 (ERK1/2) pathway by forming a holophosphatase complex that activates RAF proteins.
=== Phosphorus-32 === 32P is a radioactive isotope of phosphorus with relative atomic mass 31.973907 Da and half-life of 14.26 days. 32P is a radioactive isotope of phosphorus with beta particle-emitting radiocytotoxic activity. Emitted by 32P, beta particles directly damage cellular DNA and, by ionizing intracellular water to produce several types of cytotoxic free radicals and superoxides, indirectly damage intracellular biological macromolecules, resulting in tumor cell death.
Oxitriptan, also known as L-5-hydroxytryptophan (5-HTP) and sold under various brand names, is a medication and over-the-counter dietary supplement used in the treatment of depression and for other indications. It is taken by mouth. Side effects of oxitriptan include appetite loss, nausea, diarrhea, vomiting, and serotonin syndrome. The drug is a centrally permeable monoamine precursor and prodrug of serotonin and hence acts as a serotonin receptor agonist. Chemically, oxitriptan is an amino acid and a tryptamine. Oxitriptan has been used clinically since at least the 1970s.
(2026) report fossil evidence from the Pyvykha Mountain site (Ukraine) indicative of coexistence of archaeocetes of at least two different body size categories in the same locality during the middle Eocene, and interpret the studied cetaceans as likely to be close relatives of the ancestors of Neoceti. Van Rompaey et al. (2026) describe fossil material of Brevirostrodelphis aff. dividum and Brevirostrodelphis sp. from the Berchem Formation (Belgium), providing evidence of presence of members of this genus in the North Sea Basin and their trans-Atlantic distribution during the Miocene, and reinterpret the type specimen of Phocaenopsis sheynensis as a specimen of Kentriodon sp. The first porpoise fossil material from the western North Atlantic is reported from the Pliocene strata near Charleston (South Carolina, United States) by Kofranek et al. (2026). Tanaka et al. (2026) report the first discovery of fossil material of a toothed whale from the Miocene (Burdigalian to Langhian) strata of the Korematsu Formation (Japan). Buchholtz et al. (2026) report evidence of links between sternal shape and feeding behaviors in extant baleen whales, and reconstruct the transition from raptorial predation to filter feeding during the evolutionary history of baleen whales on the basis of the study of sternal morphology in extinct members of the group. Strauch & Pyenson (2026) report the discovery of fossil material of cf. Salishicetus from the Oligocene or Miocene strata of the Vaqueros Formation (California, United States).
A 2021 case report documented a 72‑year‑old woman with Lewy body dementia who developed fatal neuroleptic malignant syndrome (NMS) after receiving a single 156 mg intramuscular injection of paliperidone palmitate; she remained comatose and died following a prolonged hospital course after palliative care measures were initiated. The use of high‑dose, high‑potency, or long‑acting injectable formulations of antipsychotics increases the risk of developing NMS. Multiple additional case reports of NMS linked to paliperidone palmitate have been published, including a 63-year-old man (2025) who survived after treatment, and cases in a 29-year-old woman who developed severe, treatment‑refractory NMS after two doses of paliperidone palmitate (2025) and a 24-year-old man (2025).
Sources: en.wikipedia.org
=== Antimicrobial Platelets === Platelet-mimicking particles engineered with antimicrobial properties offer a novel approach to combating infections by targeting pathogens at injury sites, enhancing immune responses, and delivering antimicrobial agents directly to affected areas. While platelets are often recognized for their hemostatic role, more recent research focuses on their ability to fight infections by releasing antimicrobial molecules and through interactions with immune cells. Building on these properties, synthetic antimicrobial platelets can be an attractive targeted therapy for preventing and treating infections, particularly in trauma, surgery, and immunocompromised patients. An approach to developing antimicrobial platelet-like particles (PLPs) involves the integration of nanosilver— a material known for its potent antimicrobial activity. Recent findings have reported that nanosilver composite PNIPAM microgels incorporated into PLPs (Ag-PLPs) effectively inhibited bacterial growth while maintaining key platelet functions such as deformability and clot retraction.4 This balance is needed in order for antimicrobial synthetic platelets to induce wound healing as well as hemostasis, while keeping infection risk at minimum. Ag-PLPs, in a wound experimental model, not only increased clot retraction but also performance of healing, suggesting its regard as a "two-in-one therapy" for high-risk infection trauma patients.
On the second issue, CAS stated they could not "permit an athlete to establish how a substance came to be present in his body by little more a denial that he took it", that there was "nothing more than speculation, unsupported by any evidence of any kind", that Elsalam did not substantiate her hypothesis with any evidence aside from the receipt presented, that little attempt was made "to establish the causal link" and that it was "noteworthy" that Elsalam had not "produced a single piece of evidence demonstrating or even substantiating that other consumers (including athletes) having purchased and eating [sic] meat in Egypt within the relevant time have been subjected to food contamination with [ractopamine]" CAS upheld WADA's appeal, ruling a violation was committed, and that Elsalam had not met her burden of proof, so the violation "must be deemed to have been intentional". It was explicitly stated that they had "not pronounced the Athlete as a 'cheater'". Elsalam's ineligibility period was extended to four years. In October 2017 at a WADA conference, it was suggested in relation with ractopamine:
In an interview with Ukrainian journalist Dmytro Komarov, Vasyl Malyuk, the head of the SBU, confirmed the agency's involvement in the Crimean Bridge explosion in 2022, saying that it was being used as a logistics route by Russia.
The chain of reactions that generate reactive oxygen species (ROS) results in oxidative stress, which ultimately causes cell damage. Type II pathway of photodynamic reaction: After PS is excited into T1 state, the energy is transferred directly between PS and O2. This interaction transforms the oxygen molecules into a highly reactive form known as singlet oxygen. Singlet oxygen possesses potent oxidizing properties, making it extremely effective in reacting with and damaging cellular components. However, this reaction is selective; while most cellular components exist in a less reactive singlet state and remain unaffected, the singlet oxygen specifically targets and reacts with oxygen molecules in the cell cytoplasm. PDT is used to treat cancer across diverse types and sites. A unique feature of PDT is that photosensitizers tend to accumulate more selectively in cancer cells than in normal cells. The high affinity of photosensitizers to low-density lipoprotein (LDL) allows for selectivity. LDL acts as a carrier, allowing photosensitizers to travel into cancerous tissues. The interaction between photosensitizers and LDL makes it easier for therapeutic agents to reach the right places, which makes PDT more effective against cancer.
An oil diffusion pump is used to achieve higher vacuum (lower pressure) than is possible by use of positive displacement pumps alone. Although its use has been mainly associated within the high-vacuum range, down to 1×10−9 mbar (1×10−7 Pa), diffusion pumps today can produce pressures approaching 1×10−10 mbar (1×10−8 Pa) when properly used with modern fluids and accessories. The features that make the diffusion pump attractive for high and ultra-high vacuum use are its high pumping speed for all gases and low cost per unit pumping speed when compared with other types of pump used in the same vacuum range. Diffusion pumps cannot discharge directly into the atmosphere, so a mechanical forepump is typically used to maintain an outlet pressure around 0.1 mbar (10 Pa).
Sources: en.wikipedia.org
Jain communities established large-scale systems for animal welfare long ago. Jain merchants funded the creation of panjrapoles—specialized animal shelters and hospitals across India designed to care for sick, old, or rescued livestock and birds. The motivation behind these early shelters was not modern ethical philosophy, but the core Jain religious belief that committing violence against any living creature directly harms a person's own soul and spiritual purity. Ethical vegetarianism has become popular in developed countries particularly because of the spread of factory farming and environmental consciousness. Some believe that the current mass-demand for meat cannot be satisfied without a mass-production system that disregards the welfare of animals, while others believe that practices like well-managed free-range farming or the consumption of game (particularly from species whose natural predators have been significantly eliminated) could substantially alleviate consumer demand for mass-produced meat.
By the preponderance of American power and the absence of balance of power William Wohlforth explains the peacefulness and stability of the present world order. No distribution of power rules out war. "The greater the preponderance of power, however, the more extreme the values of other variables must be to produce war [...]" Campbell Craig believes that "Power Preponderance theory" will become one of the dominant American IR schools of the post-Cold War era:
It can also be produced by oxidising the ephedrine analogue 4-methylephedrine using potassium permanganate dissolved in sulfuric acid. Because 4-methylephedrine can be obtained in a specific enantiomeric form, mephedrone consisting of only one enantiomer can be produced. The danger associated with this method is it may cause manganese poisoning if the product is not correctly purified.
== Protactinium-231 == Protactinium-231 is the longest-lived isotope of protactinium, with a half-life of 32,760 years. In nature, it is found in trace amounts as part of the actinium series, which starts with the primordial isotope uranium-235; the equilibrium concentration in uranium ore is 46.5 atoms of 231Pa per million of 235U. In nuclear reactors, it is one of the few long-lived radioactive actinides produced as a byproduct of the projected thorium fuel cycle, as a result of (n,2n) reactions where a fast neutron removes a neutron from 232Th or 232U, and can also be destroyed by neutron capture, though the cross section for this reaction is also low.
Sources: en.wikipedia.org
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.
The primary measure is usually a cross-sectional abdominal scan that separates internal fat from fat just under the skin. Waist circumference and body weight are recorded as secondary measures because they are easy to obtain but do not distinguish the two fat compartments. Hormone and metabolic blood tests are collected alongside the imaging.
Available follow-up data indicate that visceral fat drifts back toward pretreatment levels once injections stop. The change is therefore best described as treatment-dependent rather than permanent. Investigators continue to debate whether intermittent or repeated courses would preserve any benefit.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.